OMERACT Community Forum - Recent Topics https://omeract.org/forum/ This forum provides a dedicated space for open discussion as OMERACT Working Groups move through the Core Domain Set Endorsement and Instrument Selection Ratification processes. Each Working Group has its own forum where participants can ask questions, seek clarification, and share constructive feedback. These discussions foster transparency, inclusivity, and collaboration, helping ensure all voices are heard and that participants feel confident in their understanding before completing an endorsement or ratification. en-CA Wed, 11 Mar 2026 16:38:25 +0000 wpForo 60 varying attribution to the disease in the domain definitions https://omeract.org/forum/cppd-cds/varying-attribution-to-the-disease-in-the-domain-definitions/ Thu, 30 Oct 2025 13:52:50 +0000 First of all, my compliments for a great process so far. Very clear, understandable, and reasonable.

This question pertains to the extent to which the domain is attributed to the disease. In the definitions this attribution is variable. I'm happy with any choice the group makes, but I think it would help the instrument phase if the attribution (or the lack of it) were made more explicit. My hunch is that in CPPD it makes sense to define target joints and do the assessments in those, not in the least because OA is such a concurrent condition.

Pain intensity: 'pain due to CPPD disease' but it doesn't say 'joint' even though that is added in the explanation.

Joint tenderness: ‘the affected joints’ I assume 'by the disease'?

Joint swelling: ‘joints affected by effusion or synovitis’ which suggests assessing all joints

Joint damage: no mention of affected joint, so again assessment of many joints, just a few, or only one?

]]> omeractadmin https://omeract.org/forum/cppd-cds/varying-attribution-to-the-disease-in-the-domain-definitions/ 2 different core sets or just one? https://omeract.org/forum/cppd-cds/2-different-core-sets-or-just-one/ Mon, 27 Oct 2025 12:12:20 +0000 I think you should go ahead with what you have now, we don't want to delay things. But having arrived at this point, I note the core sets show strong overlap, so in a revision you could merge them and make the differences situation-specific.

]]> Maarten Boers https://omeract.org/forum/cppd-cds/2-different-core-sets-or-just-one/ Endorsement of the OMERACT CPPD Core Domain Sets https://omeract.org/forum/cppd-cds/endorsement-of-the-omeract-cppd-core-domain-sets/ Sat, 25 Oct 2025 06:45:31 +0000 Endorsement of the OMERACT CPPD Core Domain Sets

I fully support the proposed CPPD Core Domain Sets, an excellent and methodologically robust initiative by the OMERACT CPPD Working Group.
This work provides a rigorous, patient-centered framework that will greatly enhance the consistency, comparability, and clinical relevance of CPPD research.

I would also be pleased to contribute actively to the ongoing activities and future work of the CPPD Working Group, should the opportunity arise.

Congratulations to the Working Group for this outstanding and collaborative achievement.

Francesco Caso, MD, PhD, MSc, Professor of Rheumatology, University of Naples Federico II, Naples, Italy

]]> Francesco Caso https://omeract.org/forum/cppd-cds/endorsement-of-the-omeract-cppd-core-domain-sets/ Additional considerations from the CPPD working group Discussed in working group and felt to be a circumstance dependent domain as only relevant in clinical trials evaluating structure modifying treatments. It would not make sense for all long-term s https://omeract.org/forum/cppd-cds/additional-considerations-from-the-cppd-working-group-discussed-in-working-group-and-felt-to-be-a-circumstance-dependent-domain-as-only-relevant-in-clinical-trials-evaluating-structure-modifying-treat/ Fri, 17 Oct 2025 11:16:26 +0000 As a radiologist I am a bit surprised with that final conclusion :"It would not make sense for all long-term studies to measure damage to joints on imaging. " since CPPD disease may lead to serious complications, e.g. joints instability (wrist), protrusio acetabuli, cervical spine subluxation, dens fracture, nerves compression- complications requiring constant survailance, not rarely surgical treatment.

 

 

]]> Iwona https://omeract.org/forum/cppd-cds/additional-considerations-from-the-cppd-working-group-discussed-in-working-group-and-felt-to-be-a-circumstance-dependent-domain-as-only-relevant-in-clinical-trials-evaluating-structure-modifying-treat/ Welcome to the OMERACT forums https://omeract.org/forum/guidelines-guidelines/welcome-to-the-omeract-forums/ Wed, 01 Oct 2025 14:45:58 +0000 These spaces are designed to support inclusive and constructive dialogue as Working Groups seek endorsement of their Core Domain Sets or ratification of their candidate instruments. To ensure a productive and respectful environment, please follow these guidelines:

  1. Purpose of the Forums
  • Each Working Group has its own dedicated forum.
  • Forums are intended for participants to ask questions, seek clarification, and provide constructive feedback related to the endorsement or ratification process.
  • These discussions ensure that all perspectives are considered and that participants are confident in their understanding before casting their endorsement or ratification.
  1. Respectful Engagement
  • Treat all participants—patient research partners, researchers, and collaborators—with courtesy and respect.
  • Disagreement is welcome; disrespect is not. Critique ideas, not individuals.
  • Use inclusive language and be mindful of diverse backgrounds and experiences.
  1. Staying On-Topic
  • Keep questions and comments focused on the materials and processes relevant to endorsement or ratification.
  • For unrelated OMERACT questions, please use other appropriate channels (e.g., Secretariat contact).
  1. Constructive Contributions
  • Ask clear, concise questions to support meaningful dialogue.
  • Provide feedback that is specific, actionable, and tied to the Working Group’s materials.
  • Share personal perspectives and experiences where relevant—they add richness and context to the discussion.
  1. Confidentiality & Transparency
  • Do not share confidential or draft materials outside the forum without permission.
  • Be transparent if you represent a particular collaborator group (e.g., patient, industry, policymaker).
  1. Moderation
  • Forums will be monitored by Working Group leaders and OMERACT moderators.
  • Posts that are off-topic, disrespectful, or violate these guidelines will be removed.
  1. Process Reminder
  • Participation in the forums is optional but encouraged.

Once your questions are addressed, you may proceed to complete your endorsement or ratification through the designated link.

]]> omeractadmin https://omeract.org/forum/guidelines-guidelines/welcome-to-the-omeract-forums/